Tags

Type your tag names separated by a space and hit enter

Research Units on Pediatric Psychopharmacology (RUPP) Autism Network. Background and rationale for an initial controlled study of risperidone.
Child Adolesc Psychiatr Clin N Am. 2000 Jan; 9(1):201-24.CA

Abstract

This article has reviewed the background and rationale for the choice of risperidone as the first drug to be studied by the RUPP Autism Network. Risperidone has potent effects on 5-HT and DA neuronal systems, both of which have been implicated in the pathophysiology of autism. Unlike the typical antipsychotics, haloperidol and pimozide, which have been shown to be effective for reducing many of the maladaptive behaviors associated with autism, risperidone's 5-HT2A/DA D2 ratio of receptor blockade appears to produce a lower risk of acute and chronic extrapyramidal side effects, as well as enhanced efficacy for the "negative" symptoms of autism. Indirect clinical and preclinical evidence supports the use of risperidone to treat impaired social behavior, interfering repetitive phenomena, and aggression, targets of pharmacotherapy for many patients with autism. Numerous published open-label trials in children and adolescents with autism and related PDDs and one double-blind, placebo-controlled study in adults suggest that risperidone has promise for the treatment of children and adolescents with autism. Because most of these studies have been short-term, open-label trials in small samples, however, a large-scale controlled study of risperidone in children and adolescents with autism is needed to confirm these results. Finally, because it is likely that children who demonstrate short-term benefit from risperidone will remain on the medication indefinitely, the longer-term effectiveness and safety of risperidone in this population also needs to be determined. The design of this study and the assessments used are described separately.

Authors+Show Affiliations

University School of Medicine, Indianapolis, Indiana, USA. cmcdougl@iupui.eduNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

10674197

Citation

McDougle, C J., et al. "Research Units On Pediatric Psychopharmacology (RUPP) Autism Network. Background and Rationale for an Initial Controlled Study of Risperidone." Child and Adolescent Psychiatric Clinics of North America, vol. 9, no. 1, 2000, pp. 201-24.
McDougle CJ, Scahill L, McCracken JT, et al. Research Units on Pediatric Psychopharmacology (RUPP) Autism Network. Background and rationale for an initial controlled study of risperidone. Child Adolesc Psychiatr Clin N Am. 2000;9(1):201-24.
McDougle, C. J., Scahill, L., McCracken, J. T., Aman, M. G., Tierney, E., Arnold, L. E., Freeman, B. J., Martin, A., McGough, J. J., Cronin, P., Posey, D. J., Riddle, M. A., Ritz, L., Swiezy, N. B., Vitiello, B., Volkmar, F. R., Votolato, N. A., & Walson, P. (2000). Research Units on Pediatric Psychopharmacology (RUPP) Autism Network. Background and rationale for an initial controlled study of risperidone. Child and Adolescent Psychiatric Clinics of North America, 9(1), 201-24.
McDougle CJ, et al. Research Units On Pediatric Psychopharmacology (RUPP) Autism Network. Background and Rationale for an Initial Controlled Study of Risperidone. Child Adolesc Psychiatr Clin N Am. 2000;9(1):201-24. PubMed PMID: 10674197.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Research Units on Pediatric Psychopharmacology (RUPP) Autism Network. Background and rationale for an initial controlled study of risperidone. AU - McDougle,C J, AU - Scahill,L, AU - McCracken,J T, AU - Aman,M G, AU - Tierney,E, AU - Arnold,L E, AU - Freeman,B J, AU - Martin,A, AU - McGough,J J, AU - Cronin,P, AU - Posey,D J, AU - Riddle,M A, AU - Ritz,L, AU - Swiezy,N B, AU - Vitiello,B, AU - Volkmar,F R, AU - Votolato,N A, AU - Walson,P, PY - 2000/2/16/pubmed PY - 2000/3/4/medline PY - 2000/2/16/entrez SP - 201 EP - 24 JF - Child and adolescent psychiatric clinics of North America JO - Child Adolesc Psychiatr Clin N Am VL - 9 IS - 1 N2 - This article has reviewed the background and rationale for the choice of risperidone as the first drug to be studied by the RUPP Autism Network. Risperidone has potent effects on 5-HT and DA neuronal systems, both of which have been implicated in the pathophysiology of autism. Unlike the typical antipsychotics, haloperidol and pimozide, which have been shown to be effective for reducing many of the maladaptive behaviors associated with autism, risperidone's 5-HT2A/DA D2 ratio of receptor blockade appears to produce a lower risk of acute and chronic extrapyramidal side effects, as well as enhanced efficacy for the "negative" symptoms of autism. Indirect clinical and preclinical evidence supports the use of risperidone to treat impaired social behavior, interfering repetitive phenomena, and aggression, targets of pharmacotherapy for many patients with autism. Numerous published open-label trials in children and adolescents with autism and related PDDs and one double-blind, placebo-controlled study in adults suggest that risperidone has promise for the treatment of children and adolescents with autism. Because most of these studies have been short-term, open-label trials in small samples, however, a large-scale controlled study of risperidone in children and adolescents with autism is needed to confirm these results. Finally, because it is likely that children who demonstrate short-term benefit from risperidone will remain on the medication indefinitely, the longer-term effectiveness and safety of risperidone in this population also needs to be determined. The design of this study and the assessments used are described separately. SN - 1056-4993 UR - https://www.unboundmedicine.com/medline/citation/10674197/Research_Units_on_Pediatric_Psychopharmacology__RUPP__Autism_Network__Background_and_rationale_for_an_initial_controlled_study_of_risperidone_ L2 - https://ClinicalTrials.gov/search/term=10674197 [PUBMED-IDS] DB - PRIME DP - Unbound Medicine ER -